Solana ETFs have surprised the market with more inflows than Bitcoin and Ethereum combined within the previous week. This indicates a shift in focus by investorsSolana ETFs have surprised the market with more inflows than Bitcoin and Ethereum combined within the previous week. This indicates a shift in focus by investors

Solana ETF Inflows Beat Bitcoin and Ethereum With SOL Eyeing $190 Target

Solana ETFs have surprised the market with more inflows than Bitcoin and Ethereum combined within the previous week. This indicates a shift in focus by investors. The capital is experiencing a rotation to high-performance blockchains. Solana’s speedy transactions, low costs, and usage in DeFi and on-chain applications are to its advantage.

Source: X

The data also indicates an increasing risk appetite from investors who are looking at growing alternatives to BTC and ETH. Network stability and developments are also restoring investor confidence in Solana, and fixed ETF demand may solidify its place in a new crypto market.

Also Read: Solana (SOL) Eyes $1,000 Long-Term Target Amid Major Revenue Surge in 2025

SOL Eyes $190 as Head and Shoulders Pattern Emerges

However, the crypto analyst, Peak, revealed that Solana (SOL) is at a critical level as it settled into a head and shoulders formation on the daily chart. The level to watch is the $124 support zone, as it is a region where buyers have flocked in the past. If it holds, the correction may see a relief rally as the selling pressure drops.

Source: X

With an effective defense of the $124 level, it may allow SOL to continue to press higher towards the target at $190. Conversely, a breakdown from the support level would confirm the bearish scenario and allow the contract to continue to fall towards the target.

Indicators Shows Stability Before The Next Big Move

On the weekly chart of SOL, the market condition appears to be range-bound with a slightly bearish trend. The RSI index is at the level of 43, which is lower than the midpoint of 50. This indicates that the momentum of the market is weak. However, the recent recovery from the lower level indicates that the selling momentum may be slowing down rather than gaining further strength.

Source: TradingView

MACD remains below the zero line, showing that the overall market is technically bearish, although the histogram has changed color to positive, implying that there is reducing bearish momentum. These two aspects together imply that there is stabilization rather than a trend reversal at this early stage.

Also Read: Solana Price Under Watch After $43M Whale Short Position

Market Opportunity
Audiera Logo
Audiera Price(BEAT)
$1,37713
$1,37713$1,37713
-0,01%
USD
Audiera (BEAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Media & Crypto.com Partner For Shareholder Token Airdrop

Trump Media & Crypto.com Partner For Shareholder Token Airdrop

Trump Media & Technology Group (NASDAQ:DJT) has announced plans to distribute a new digital token to its shareholders, leveraging Crypto.com‘s infraread more
Share
Coinstats2026/01/01 00:23
Tria’s $20m beta surge: How a self-custodial neobank is redefining onchain finance

Tria’s $20m beta surge: How a self-custodial neobank is redefining onchain finance

CEO Vijit Katta shares with crypto.news how Tria is reshaping digital asset banking and paving the way for a frictionless, user-controlled financial future.
Share
Crypto.news2026/01/01 01:00
The FDA Is Trying To Make Corporate Free Speech Situational

The FDA Is Trying To Make Corporate Free Speech Situational

The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…
Share
BitcoinEthereumNews2025/09/18 06:29